Genmab A/S
- Last sale
- Nov 12, 2026 · -4.01%
- Market cap
- —
- no share count on file
- Filings
- 573
FY 2025+19.2% FY25 yoy
FY 2025−15.0% FY25 yoy
FY 2025+9.6% FY25 yoy
FY 2025derived+4.5% FY25 yoy
FY 2025−12.3% FY25 yoy
FY 2025+24.3% FY25 yoy
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3,720,000,000 | reported | |
| FY 2024 | 2024-12-31 | $3,121,000,000 | reported | |
| FY 2023 | 2023-12-31 | $2,390,000,000 | reported |
Segments
Geography
LineFY2025ShareChange
Denmark$3.33B89%+16.0%
Japan$213.00M5.7%+74.6%
United States$180.00M4.8%+37.4%
Netherlands$1.00M0.0%—
China$0.00——
Total$3.72B
Pharmaceutical preparations
Genmab A/S is the 21st largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BELANElanco Animal Health Inc$4.7B6.2%4.9%$13.3BJAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4BPRGOPerrigo Co PLC$4.3B2.8%33.5%$2.2B
GMABGenmab A/S (this company)$3.7B19.2%25.9%—
ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BBMRNBioMarin Pharmaceutical Inc$3.2B12.9%10.8%$11.0BUTHRUnited Therapeutics Corp$3.2B10.6%41.9%$25.3BAMRXAmneal Pharmaceuticals, Inc.$3.0B8.0%2.4%$7.5BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Genmab A/S · CIK 1434265 · Engraved from SEC EDGAR